title: Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics.
abstract: Despite unmet needs for cardiovascular biomarkers, few new protein markers have been approved by the US Food and Drug Administration for the diagnosis or screening of cardiovascular diseases. Mass spectrometry-based proteomics technologies are capable of identifying hundreds to thousands of proteins in cells, tissues, and biofluids. Proteomics may therefore provide the opportunity to elucidate new biomarkers and pathways without a prior known association with cardiovascular disease; however, important obstacles remain. In this review, we focus on emerging techniques that may form a coherently integrated pipeline to overcome present limitations to both the discovery and validation processes.
authors.affiliation: Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, 02114, USA.
authors.forename: Robert E
authors.initials: RE
authors.lastname: Gerszten
authors.forename: Aarti
authors.initials: A
authors.lastname: Asnani
authors.forename: Steven A
authors.initials: SA
authors.lastname: Carr
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000032:analysis; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000378:metabolism; D006801:Humans; D013058:Mass Spectrometry; D011237:Predictive Value of Tests; D011379:Prognosis; D011506:Proteins / Q000032:analysis*; D040901:Proteomics / Q000379:methods; D015203:Reproducibility of Results
chemical_list: D015415:Biomarkers; D011506:Proteins